VSL#3 probiotic mixture: a review of its use in chronic inflammatory bowel diseases.
about
Probiotics for induction of remission in Crohn's diseaseProbiotics modulate intestinal expression of nuclear receptor and provide counter-regulatory signals to inflammation-driven adipose tissue activationSystematic review of randomized controlled trials of probiotics, prebiotics, and synbiotics in inflammatory bowel diseasePost-translational inhibition of IP-10 secretion in IEC by probiotic bacteria: impact on chronic inflammation.Potential role of nutraceutical compounds in inflammatory bowel diseaseProbiotics for the treatment of Clostridium difficile associated disease.Probiotics to counteract biofilm-associated infections: promising and conflicting dataVSL#3 induces and maintains short-term clinical response in patients with active microscopic colitis: a two-phase randomised clinical trialProduction Conditions Affect the In Vitro Anti-Tumoral Effects of a High Concentration Multi-Strain Probiotic Preparation.Nutritional modulators of ulcerative colitis: clinical efficacies and mechanistic viewDrug therapy of inflammatory bowel disease in fertile women.Probiotic products in Canada with clinical evidence: what can gastroenterologists recommend?Efficacy profiles for different concentrations of Lactobacillus acidophilus in experimental colitisTherapeutic effects of four strains of probiotics on experimental colitis in miceImportance of nutrition in inflammatory bowel disease.Rationale for probiotic treatment strategies in inflammatory bowel disease.Balsalazide in treating colonic diseases.Therapy of inflammatory bowel diseases in pregnancy and lactation.Lessons from probiotic-host interaction studies in murine models of experimental colitis.The role of probiotics and prebiotics in inducing gut immunity.VSL#3 probiotic differently influences IEC-6 intestinal epithelial cell status and function.Intestinal microbiota, fecal microbiota transplantation, and inflammatory bowel disease.Probiotic supplementation and trimethylamine-N-oxide production following a high-fat diet.Can Probiotics Reduce Inflammation and Enhance Gut Immune Health in People Living with HIV: Study Designs for the Probiotic Visbiome for Inflammation and Translocation (PROOV IT) Pilot Trials.Type 1 Diabetes: Urinary Proteomics and Protein Network Analysis Support Perturbation of Lysosomal FunctionHost-probiotic interaction: new insight into the role of the endocannabinoid system by in vivo and ex vivo approaches.Pharmacokinetics of verapamil and its metabolite norverapamil in rats with hyperlipidaemia induced by poloxamer 407.Effects of a Lactobacillus reuteri BR11 mutant deficient in the cystine-transport system in a rat model of inflammatory bowel disease.Balancing inflammatory, lipid, and xenobiotic signaling pathways by VSL#3, a biotherapeutic agent, in the treatment of inflammatory bowel disease.Oral therapeutic administration of a probiotic mixture suppresses established Th2 responses and systemic anaphylaxis in a murine model of food allergy.
P2860
Q24242115-5D46D36F-23E1-4D21-AC95-5748278979CAQ27327276-73815E39-705C-4487-89BA-E739F043DD24Q28254207-F60E1197-6B34-49B3-9D37-05A67E2D2218Q33406281-662B390B-2C2A-4032-9CD6-8791F2E44F17Q33572633-9D8A8C3A-8652-4006-978C-AB0D0AEED6CCQ34364074-5E3F67DD-75B4-4E18-A547-A1FB57F1F5DCQ35278680-B2FADC86-2FA5-4DA2-BCCA-AAD1DC0A50ABQ36140404-32AEB4A6-9DA8-40D7-A541-F66CA4A8BFD6Q36140994-29A8E53F-F30F-4F42-AA38-73FB5908C649Q36637753-37C5394C-4BED-4E35-8D6F-D66451D2A6A1Q36687466-821777BA-DED1-436A-ADF2-5B3C04B34691Q37094595-920A2BD8-1B21-4646-93D4-5BE546795CADQ37118873-13F4A61F-E720-441A-AAC2-9A668CDE0DD4Q37122235-498399CA-B4FA-4CD9-93E7-0C831F9F02C5Q37182945-20E78032-0225-40BB-B12D-1DFCCBB163C2Q37345932-583AB155-F0E7-41A2-B8D9-C0CD04D60A09Q37587217-F7DF362A-26E8-46F0-9193-B3985E69AD45Q37615417-174EB910-C6E6-4E00-A04B-25D4A52EC223Q37907198-A5B939EC-4202-43B8-A4D9-D41B7CE4014BQ38174603-28F5FCE9-B867-4308-9472-CE53F8A3734EQ38720190-B29E02A4-D3BE-42E6-94C3-7D86CEA198C1Q38727911-B35C76CB-0167-48AB-A6D8-06EA2BF99029Q38953644-B1FDF312-4B14-4A44-9929-8BFE2005A9D8Q40643518-738308F1-6909-4A7C-B5E0-7519C1F08315Q41430377-3D61D9D4-1964-49D0-B179-9714215CB063Q42268439-7941ACF7-89D7-47C0-8822-2F3B7930C8A1Q43937782-1990A68E-4E98-4A31-A6FF-071E4AF57E50Q44023499-13FC41D1-76F6-4CB5-955B-2AF46228A096Q46495260-D9D1F788-7BDB-4191-A5A7-B5FC6267EA80Q54402802-6B23CAA3-37BD-46F3-B783-C004BE411377
P2860
VSL#3 probiotic mixture: a review of its use in chronic inflammatory bowel diseases.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
VSL#3 probiotic mixture: a review of its use in chronic inflammatory bowel diseases.
@ast
VSL#3 probiotic mixture: a review of its use in chronic inflammatory bowel diseases.
@en
type
label
VSL#3 probiotic mixture: a review of its use in chronic inflammatory bowel diseases.
@ast
VSL#3 probiotic mixture: a review of its use in chronic inflammatory bowel diseases.
@en
prefLabel
VSL#3 probiotic mixture: a review of its use in chronic inflammatory bowel diseases.
@ast
VSL#3 probiotic mixture: a review of its use in chronic inflammatory bowel diseases.
@en
P921
P1433
P1476
VSL#3 probiotic mixture: a review of its use in chronic inflammatory bowel diseases.
@en
P2093
Therese M Chapman
P304
P356
10.2165/00003495-200666100-00006
P577
2006-01-01T00:00:00Z
P6179
1012272699